• 1. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 2. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 3. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 4. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 5. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831

Comprehensive Overview of (R)-4-(tert-Butoxy)-2-isopropyl-4-oxobutanoic Acid (CAS No. 389843-61-2)

The compound (R)-4-(tert-Butoxy)-2-isopropyl-4-oxobutanoic Acid (CAS No. 389843-61-2) is a chiral organic molecule with significant applications in pharmaceutical synthesis and fine chemical industries. Its unique structure, featuring a tert-butoxy group and an isopropyl moiety, makes it a valuable intermediate for asymmetric synthesis. Researchers and manufacturers are increasingly interested in this compound due to its role in producing high-purity enantiomers, a critical requirement in modern drug development.

In recent years, the demand for chiral compounds like (R)-4-(tert-Butoxy)-2-isopropyl-4-oxobutanoic Acid has surged, driven by the growing focus on precision medicine and personalized therapeutics. The compound's CAS No. 389843-61-2 is frequently searched in academic databases and chemical marketplaces, reflecting its relevance in cutting-edge research. Its applications span from catalysts in asymmetric reactions to building blocks for bioactive molecules, aligning with trends in green chemistry and sustainable synthesis.

One of the key advantages of (R)-4-(tert-Butoxy)-2-isopropyl-4-oxobutanoic Acid is its stability under various reaction conditions, making it a preferred choice for multi-step synthetic routes. The tert-butoxy group enhances solubility in organic solvents, while the isopropyl substituent contributes to steric control during stereoselective transformations. These properties are particularly valuable in the synthesis of APIs (Active Pharmaceutical Ingredients), where enantiomeric purity is paramount.

From an industrial perspective, scalability and cost-effectiveness are critical factors for compounds like 389843-61-2. Recent advancements in continuous flow chemistry and biocatalysis have opened new avenues for its large-scale production, addressing challenges such as yield optimization and waste reduction. These innovations resonate with the pharmaceutical industry's push toward greener and more efficient manufacturing processes.

Analytical techniques such as HPLC, NMR, and mass spectrometry are essential for characterizing (R)-4-(tert-Butoxy)-2-isopropyl-4-oxobutanoic Acid, ensuring compliance with stringent regulatory standards. The compound's chiral purity is often verified using chiral stationary phases, a topic of high interest in analytical chemistry forums. Additionally, its spectral data (e.g., IR and UV-Vis profiles) are widely documented, facilitating its identification in complex mixtures.

In the context of intellectual property, CAS No. 389843-61-2 has been referenced in several patents related to antiviral and anti-inflammatory agents. This highlights its potential as a scaffold for novel therapeutics, a trending topic in medicinal chemistry. Researchers are also exploring its derivatives for applications in agrochemicals and specialty materials, further expanding its commercial viability.

For laboratories and manufacturers sourcing (R)-4-(tert-Butoxy)-2-isopropyl-4-oxobutanoic Acid, quality control is a top priority. Certificates of Analysis (CoA) detailing assay purity, enantiomeric excess, and residual solvents are indispensable. Suppliers often emphasize these metrics in product listings, catering to the needs of quality-conscious buyers in regulated industries.

Looking ahead, the compound's role in emerging fields like PROTACs (Proteolysis Targeting Chimeras) and peptide mimetics is under investigation. Such applications align with the broader shift toward targeted therapies and biologics, which dominate current pharmaceutical R&D. As a result, 389843-61-2 is poised to remain a compound of interest in both academic and industrial settings.

• 90016-14-1(1,2,3-Propanetricarboxylic acid, 1-(1,1-dimethylethyl) 2,3-diethyl ester)
• 153427-69-1(2-(R)-Pentylsuccinic Acid 4-tert-Butyl Ester)
• 200866-61-1((R)-(+)-2-Butylbutanedioic acid 4-tert-butyl ester)
• 136749-31-0(1,3,4,6-Hexanetetracarboxylic acid, 1,6-bis(1,1-dimethylethyl) 3,4-dimethyl ester, (R*,R*)- (9CI))
• 692778-50-0((2R,3S)-2-(2-tert-Butoxy-2-oxoethyl)-3-methyl-pentanoic acid)
• 71648-27-6(Hexanoic acid,2-ethyl-, 1,1-dimethylethyl ester)
• 140408-50-0(Pentanedioic acid, 2-methyl-, 5-(1,1-dimethylethyl) ester, (R)-)
• 153427-89-5(Butanedioic acid, octyl-, 4-(1,1-dimethylethyl) ester, (R)-)
• 163389-15-9(Butanedioic acid, pentyl-, 1-(1,1-dimethylethyl) ester, (R)-)
• 163389-16-0(Butanedioic acid, hexyl-, 1-(1,1-dimethylethyl) ester, (R)-)